【摘要】：目的：探討分析扶正抗癌方干預(yù)的晚期非小細(xì)胞肺癌長期生存患者(生存期2年)的預(yù)后相關(guān)因子,為優(yōu)化提高晚期非小細(xì)胞肺癌中西醫(yī)結(jié)合治療方案提供臨床參考依據(jù)。方法：本研究采用回顧性研究方法,收集廣東省中醫(yī)院腫瘤科2006年1月至2015年12月于吳萬垠教授門診以及病房接受扶正抗癌方治療的晚期非小細(xì)胞肺癌、獲得長期生存病例(生存期2年),將符合納入標(biāo)準(zhǔn)的113例患者,通過對生存時間可能產(chǎn)生影響的個人臨床特征、腫瘤及治療相關(guān)因子共39項進(jìn)行分析。并建立數(shù)據(jù)庫,運用Kaplan-Meier法聯(lián)合Log-Rank檢驗進(jìn)行單因素分析；運用Cox比例風(fēng)險回歸模型進(jìn)行多因素分析(檢驗水平α=0.05),篩選危險因子和保護(hù)因子。結(jié)果：截至2016年3月1日,共納入113例患者,其中56例死亡,其余57例為截尾數(shù)據(jù)。所有患者3、4、5年生存率分別為51.3%、26.5%、12.4%,其中位生存時間為36.4月(95% CI：32.0-40.8月)。單因素分析顯示性別、吸煙史、PS評分、體重減輕、原發(fā)腫瘤大小、合并胸水、病理類型、淋巴結(jié)分期、中醫(yī)證型、扶正抗癌方干預(yù)時間與晚期非小細(xì)胞肺癌長期生存相關(guān)(PO.05)。多因素分析顯示PS評分、原發(fā)腫瘤大小、淋巴結(jié)分期、中醫(yī)證型、扶正抗癌方干預(yù)時間為晚期非小細(xì)胞肺癌長期生存的獨立預(yù)后因素。其中,PS≥12分、原發(fā)腫瘤7cm、 N3、氣陰兩虛型、熱毒熾盛型、扶正抗癌方干預(yù)時間≤24個月,為晚期非小細(xì)胞肺癌長期生存的預(yù)后危險因子。結(jié)論：1.PS評分、原發(fā)腫瘤大小、淋巴結(jié)分期、中醫(yī)證型、扶正抗癌方干預(yù)時間能影響晚期非小細(xì)胞肺癌長期生存。2.中藥扶正抗癌方在延長晚期非小細(xì)胞肺癌生存時間方面有一定的治療作用,值得進(jìn)一步研究。
[Abstract]:Objective: to investigate the prognostic factors of patients with advanced non-small cell lung cancer (NSCLC) treated with Fuzheng Fang (Fuzheng Fang), and to provide a clinical reference for optimizing and improving the treatment of advanced non-small cell lung cancer (NSCLC) with combination of traditional Chinese and western medicine. Methods: a retrospective study was conducted to collect advanced non-small cell lung cancer (NSCLC) from January 2006 to December 2015 in Professor Wu Wanyin's outpatient clinic and ward treated with Fuzheng Fang. The long-term survival cases (survival time 2 years) were obtained. 113 patients who met the inclusion criteria were analyzed through 39 items of individual clinical characteristics, tumor and treatment-related factors that might have an impact on survival time. The database was established, and the single factor analysis was carried out by Kaplan-Meier method combined with Log-Rank test, and the multivariate analysis was carried out by using the Cox proportional risk regression model (test level 偽 0. 05), and the risk factors and protection factors were screened. Results: as of March 1, 2016, 113 patients were included, 56 of whom died and the remaining 57 were amputations. The 5-year survival rates of all patients were 51.3% and 26.5%, respectively, and the survival time was 36.4 months (95% CI:32.0-40.8 / month). Univariate analysis showed that sex, smoking history and PS score, weight loss, primary tumor size, combined pleural effusion, pathological type, lymph node staging, TCM syndrome type and intervention time of Fuzheng Fang were associated with long-term survival of advanced non-small cell lung cancer (PO.05). Multivariate analysis showed that PS score, primary tumor size, lymph node staging, TCM syndrome type and intervention time of Fuzheng Fang were independent prognostic factors for long-term survival of advanced non-small cell lung cancer. Among them, PS 鈮，

本文編號：2257433